Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
about
Interventions for preventing oral candidiasis for patients with cancer receiving treatmentTreatment with echinocandins during continuous renal replacement therapySingle or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Safety and pharmacokinetics of repeat-dose micafungin in young infants.Pharmacokinetics of an elevated dosage of micafungin in premature neonates.Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.Micafungin use in children.Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.Echinocandins: the newest class of antifungals.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patientsMicafungin in the treatment of invasive candidiasis and invasive aspergillosisEchinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people.Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTsOnce-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaFluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Altered Micafungin Pharmacokinetics in Intensive Care Unit PatientsDifferential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Micafungin: a new echinocandin antifungal.The echinocandins.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.Micafungin for the prophylaxis and treatment of Candida infections.Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasisEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.Paradoxical echinocandin activity: a limited in vitro phenomenon?Review of the pharmacology and clinical studies of micafunginSafety of micafungin in infants: insights into optimal dosing.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Safety and interactions of new antifungals in stem cell transplant recipients.Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.The Eagle-like effect of echinocandins: what's in a name?Impact of special patient populations on the pharmacokinetics of echinocandins.Echinocandins: The Expanding Antifungal Armamentarium.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
P2860
Q24243005-D12140F1-8115-4C29-90D8-F775A4CA4F9BQ27012864-59377704-4036-44A7-BB6E-0DABEDE15614Q28082570-F41DE293-062F-4A10-A1BF-9B54DC987EBCQ30433612-3EC38E55-6193-4D1A-9F60-877A776BAE54Q30436332-C12DA6E0-2B7D-4A11-A48C-F708F18D4B41Q31075176-DBC6DBE2-3A11-4347-AC1E-150D72169F8CQ33397111-77860E56-562D-48A8-A061-800430243144Q33816237-2DFAC12B-AC02-47D5-BDFE-5C941B2C57DBQ33898397-5060576D-8A28-4EFB-84EF-B615B7003161Q34019188-6C35D969-23F4-45DB-99E7-BA60F39F91E0Q34045450-B07BFA1C-B93D-48B0-B35A-37FE26E928E1Q35026516-E05B1FD9-AE65-4035-9D31-3FF6E3079DC8Q35140020-64F7EF0A-F7E2-4EC9-B157-51E6D90231C8Q35363785-6294E0B4-7040-4BB1-BCE1-146ADF6E3FA3Q35515892-2A29A243-CDAB-4D3C-85B0-46974F83B4CCQ35647785-7429EF63-069A-41B0-80A0-7BF4BBA0188CQ35746253-A19D2497-C54E-4AE2-89C2-DF5ED8F674A5Q35860004-EE7868BE-2F85-4947-815E-05BAC7F1ACB2Q35941237-271DD9C1-166D-41FA-9C1B-3A857EEAE8D1Q36505508-A13A71BB-016E-4292-B28B-2BBF948F1FD6Q36626518-117401F5-7E35-4549-8546-0A5CD8E9228CQ36693843-C039237E-3FED-4EA7-B1A6-0F247E3C7E9AQ36742397-41761B65-46BA-42CA-9774-9686CF7B53C2Q36825717-5E4B9A8D-3CED-4C68-ADC1-0D6D74112374Q36828156-0027E34B-347B-4982-B9F8-043BB4DEBFD2Q36867925-96422DA4-2BB9-4092-883A-DE0113AD176EQ36895679-B07E166A-04CC-4E2A-B177-244ECC9423B4Q37124868-A86CB9EC-B99D-4955-8348-1BEBCA4A2109Q37283043-299034BD-CE3B-4954-9A0A-42BD34C0F408Q37291442-6711801F-16E6-46F0-BC06-B7F217D68E9BQ37405284-CEA8F67F-9383-4627-A93C-6C89686B0B6DQ37669740-D6819570-FC1D-4155-80DF-CBFA87305F21Q37827883-45D2C298-067F-4259-8A5D-4D51EE54B157Q37918556-9A23DD17-200B-4F17-AF08-F8759D481C54Q38036740-14CB6CF6-DE57-4EFB-8DB2-E4F54629DEACQ38053482-9C1EA95F-7A74-4910-B578-2A1104D607D3Q38153458-A2F2C84A-59C3-416E-A2FC-DBD54E6C0227Q38462784-75345C41-D16F-4B77-A934-4E226384EBE2Q38633102-6126DE30-C7F1-4766-9ADA-1526F57909C3Q38681635-FD4DC090-C22F-44C1-A677-263DD011356A
P2860
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@ast
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@en
type
label
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@ast
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@en
prefLabel
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@ast
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@en
P2093
P2860
P1476
Pharmacokinetic and maximum to ...... ripheral stem cell transplant.
@en
P2093
P2860
P304
P356
10.1128/AAC.49.4.1331-1336.2005
P407
P577
2005-04-01T00:00:00Z